Effectiveness of budesonide nebulising suspension compared to disodium cromoglycate in early childhood asthma

Authors: Zielen, S.1; Rose, M.A.1; Bez, C.1; Jarisch, A.1; Reichenbach, J.1; Hofmann, D.1

Source: Current Medical Research and Opinion, Volume 22, Number 2, February 2006 , pp. 367-373(7)

Publisher: Informa Healthcare

Purchase options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$51.50 plus tax      Refund Policy

OR

 
More about this publication?
More like this?
Content Key:
Free Content - Free
New Content - New
Open Access Content - Open Access
Subscribed Content - Subscribed
Free Trial Content - Free Trial

Abstract:

Objective: The optimal treatment for early childhood asthma remains controversial. Budesonide (BUD) has shown superiority over placebo in infants, and over disodium cromoglycate (DSCG) in children aged > 2 years. The aim of this double-blind, randomised, parallel-group study was to compare the effectiveness of nebulised BUD and DSCG in asthmatic children aged < 36 months.

Research design and methods: 82 infants (mean age 18.0 months [range, 11.6–31.2 months]) with suspected asthma (three exacerbations of dyspnoea and wheezing during the past 12 months, with one or more exacerbations in the past 3 months) were treated for 3 months with nebulised BUD (Pulmicort Respules) 0.5 mg/2 mL bid or DSCG 20 mg/2 mL tid. Follow-up was at 6 months.

Main outcome measures and results: Patients treated with BUD had a lower exacerbation rate than DSCG-treated patients after 3 months of treatment (5.4% vs. 31.7%; p = 0.003) and towards the end of follow-up (30% vs. 49%; p = 0.062). During treatment, days without cough were 80% and 65% for BUD and DSCG, respectively (p = 0.014), and nights without cough were 89% and 78%, respectively (p = 0.016). Side-effects were mild and of similar frequency in both groups.

Conclusions: Inhaled nebulised BUD was well tolerated and more effective than nebulised DSCG in reducing the incidence of asthma exacerbations and days with symptoms. These beneficial effects of BUD were maintained throughout the 6-month follow-up.

Keywords: ASTHMA; DISODIUM CROMOGLYCATE; GROWTH; NEBULISED BUDESONIDE; PRESCHOOL CHILDREN

Document Type: Research article

DOI: 10.1185/030079906X89739

Affiliations: 1: J. W. Goethe-University, Children's Hospital, Frankfurt/Main, Germany

Back to top

Content Key:
Free Content - Free
New Content - New
Open Access Content - Open Access
Subscribed Content - Subscribed
Free Trial Content - Free Trial
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in
Need to register?
Sign up here
Text size: A | A | A | A